

## CSD/BSE&NSE/CC/2024-25 December 1, 2024

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex

Bandra (E), Mumbai – 400 051

Scrip Code: 543064 Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding Analyst/Institutional Investor Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the management of the Company will be attending the below mentioned conference/roadshow:

Date	Conference/Roadshow			Location	Group/One-on-one
December 4, 2024	BOB	Capital	Market	Virtual	Group/One-on-one
	interactive session				

No unpublished price-sensitive information will be shared during this interaction.

Note: The schedule of the aforesaid meetings is subject to change. The change may happen due to exigencies on the part of Analyst/Institutional Investor/Company.

You are requested to take this information on records.

Thanking You.

Yours faithfully,

For Suven Pharmaceuticals Limited

## Kundan Kumar Jha

Company Secretary, Compliance Officer and Head-Legal

## Suven Pharmaceuticals Limited

**Registered Office:** # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India Tel: 91 22 61539999

**Corporate Office:** # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081 Telangana, India Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236